Theriva Biologics Future Growth

Future criteria checks 0/6

Theriva Biologics's earnings are forecast to decline at 8.9% per annum while its annual revenue is expected to grow at 100.3% per year. EPS is expected to grow by 48.4% per annum.

Key information

-8.9%

Earnings growth rate

48.4%

EPS growth rate

Biotechs earnings growth	42.2%
Revenue growth rate	100.3%
Future return on equity	n/a
Analyst coverage	Low
Last updated	12 Nov 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:SFY0 - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	-41	N/A	N/A	1
12/31/2025	N/A	-36	N/A	N/A	1
12/31/2024	N/A	-22	N/A	N/A	1
9/30/2024	N/A	-27	-19	-19	N/A
6/30/2024	N/A	-22	-18	-18	N/A
3/31/2024	N/A	-19	-18	-18	N/A
12/31/2023	N/A	-18	-19	-19	N/A
9/30/2023	N/A	-19	-18	-18	N/A
6/30/2023	N/A	-21	-19	-19	N/A
3/31/2023	N/A	-20	-20	-20	N/A
12/31/2022	N/A	-20	-19	-19	N/A
9/30/2022	N/A	-19	-19	-19	N/A
6/30/2022	N/A	-17	-16	-16	N/A
3/31/2022	N/A	-16	-14	-14	N/A
12/31/2021	N/A	-23	-13	-13	N/A
9/30/2021	N/A	-21	-11	-11	N/A
6/30/2021	N/A	-20	-11	-11	N/A
3/31/2021	N/A	-21	-11	-11	N/A
12/31/2020	N/A	-13	-12	-12	N/A
9/30/2020	N/A	-13	-13	-13	N/A
6/30/2020	N/A	-15	-14	-14	N/A
3/31/2020	N/A	-16	-15	-15	N/A
12/31/2019	N/A	-16	-14	-14	N/A
9/30/2019	N/A	-28	-14	-14	N/A
6/30/2019	N/A	-26	-14	-14	N/A
3/31/2019	N/A	-27	-15	-15	N/A
12/31/2018	N/A	-25	-17	-17	N/A
9/30/2018	N/A	-8	-18	-18	N/A
6/30/2018	N/A	-22	N/A	-19	N/A
3/31/2018	N/A	-22	N/A	-20	N/A
12/31/2017	N/A	-22	N/A	-20	N/A
9/30/2017	N/A	-27	N/A	-27	N/A
6/30/2017	N/A	-18	N/A	-28	N/A
3/31/2017	N/A	-19	N/A	-28	N/A
12/31/2016	N/A	-27	N/A	-28	N/A
9/30/2016	N/A	-36	N/A	-28	N/A
6/30/2016	N/A	-34	N/A	-38	N/A
3/31/2016	N/A	-42	N/A	-39	N/A
12/31/2015	N/A	-44	N/A	-39	N/A
9/30/2015	N/A	-39	N/A	-33	N/A
6/30/2015	N/A	-37	N/A	-22	N/A
3/31/2015	N/A	-28	N/A	-18	N/A
12/31/2014	N/A	-20	N/A	-16	N/A
9/30/2014	N/A	-18	N/A	-14	N/A
6/30/2014	N/A	-16	N/A	-11	N/A
3/31/2014	N/A	-14	N/A	-10	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SFY0 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SFY0 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SFY0 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SFY0 is forecast to have no revenue next year.

High Growth Revenue: SFY0 is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SFY0's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/11/20 00:32
End of Day Share Price	2024/08/23 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Theriva Biologics, Inc. is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
James Molloy	Alliance Global Partners
Keay Nakae	Ascendiant Capital Markets LLC
Timothy Chiang	BTIG

Theriva Biologics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Theriva Biologics, Inc. has filed a Follow-on Equity Offering.

Theriva Biologics, Inc. Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma

Theriva Biologics, Inc. Announces Positive Outcome of Data and Safety Monitoring Committee (Dsmc) Review in Phase 1B/2A Clinical Trial of Syn-004 (Ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Theriva Biologics, Inc., Annual General Meeting, Oct 31, 2024

High number of new and inexperienced directors

Theriva Biologics, Inc. has filed a Follow-on Equity Offering.

New minor risk - Shareholder dilution

New major risk - Financial position

Theriva Biologics, Inc. Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma

Theriva Biologics, Inc Announces U.S. Food and Drug Administration Granted Fast Track Designation

Theriva Biologics, Inc. has filed a Follow-on Equity Offering in the amount of $1.235303 million.

Theriva Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma

Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma

Theriva™ Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023

Theriva Biologics, Inc. Announces Presentation at Esmo Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating Vcn-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

Theriva Biologics, Inc., Annual General Meeting, Oct 02, 2023

New minor risk - Shareholder dilution

New major risk - Market cap size

Theriva Biologics Appoints Ramon Alemany as Senior VP of Discovery

Theriva Biologics, Inc. Announces Presentation of Safety and Pharmacokinetic Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Theriva Biologics, Inc. Announces First Patient Dosed in VIRAGE, A Phase 2B Trial of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma

Theriva Biologics Announces Dosing of First Patient in the Investigator Sponsored Phase 1 Trial of VCN-01, an Intravenous Oncolytic Adenovirus, in Patients with Brain Tumors

High number of new and inexperienced directors

Theriva Biologics Announces First Patient Dosed in Second Cohort of Phase 1b/2a Clinical Trial of SYN-004

Theriva Biologics, Inc. Announces Presentation at the 14th International Oncolytic Virotherapy (IVOC) Conference Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

Synthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (Dsmc) Review in Phase 1B/2A Clinical Trial of Syn-004 (Ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

Synthetic Biologics, Inc., Annual General Meeting, Sep 30, 2022

Synthetic Biologics, Inc. announced that it expects to receive $3 million in funding from MSD Partners, L.P.

Synthetic Biologics, Inc. Notifies Clearance of Safety Evaluation Period

High number of new and inexperienced directors

Synthetic Biologics, Inc. Reports Positive Safety Data on Syn-020 Intestinal Alkaline Phosphatase Phase 1 Multiple Ascending Dose Clinical Trial

Synthetic Biologics Announces Formation of Scientific Advisory Board to Advance Oncology Pipeline

Synthetic Biologics, Inc. Announces Peer-Reviewed Publication of Phase 1 Trial of Intravenous VCN-01 Oncolytic Adenovirus in Patients with Advanced Solid Tumors

Synthetic Biologics, Inc. (NYSEAM:SYN) signed a definitive agreement to acquire VCN Biosciences SL from Grifols Innovation and New Technologies Limited and others for $85.6 million.

Synthetic Biologics Provides Update on Syn-020 Intestinal Alkaline Phosphatase Phase 1 Single-Ascending Dose Clinical Trial

Synthetic Biologics Regains Compliance with NYSE American Continued Listing Standards

Synthetic Biologics, Inc. Announces Clinical Development and Operational Update

Insider recently bought €144k worth of stock

Synthetic Biologics, Inc. to Report Fiscal Year 2020 Results on Mar 04, 2021

New 90-day high: €1.23

Synthetic Biologics, Inc. Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol

Synthetic Biologics Announces Extension of Compliance Plan Period by NYSE American

Synthetic Biologics, Inc. Announces Executive Changes

Synthetic Biologics, Inc. to Report Q3, 2020 Results on Nov 10, 2020

New 90-day low: €0.23

New 90-day low: €0.24

Synthetic Biologics Provides Update on Investigator-Sponsored Phase 2B Clinical Study of SYN-010 in IBS-C Patients

New 90-day low: €0.37

New 90-day high - €0.59

Synthetic Biologics, Inc. to Report Q2, 2020 Results on Aug 06, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources